158 related articles for article (PubMed ID: 34766583)
1. CYP1A2 polymorphism may contribute to agomelatine-induced acute liver injury: Case report and review of the literature.
Wang S; Xu Q; Qu K; Wang J; Zhou Z
Medicine (Baltimore); 2021 Nov; 100(45):e27736. PubMed ID: 34766583
[TBL] [Abstract][Full Text] [Related]
2. Effect of CYP1A2 polymorphism on the pharmacokinetics of agomelatine in Chinese healthy male volunteers.
Song L; Du Q; Jiang X; Wang L
J Clin Pharm Ther; 2014 Apr; 39(2):204-9. PubMed ID: 24372004
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms in CYP1A2, CYP2C9 and ABCB1 affect agomelatine pharmacokinetics.
Saiz-Rodríguez M; Ochoa D; Belmonte C; Román M; Vieira de Lara D; Zubiaur P; Koller D; Mejía G; Abad-Santos F
J Psychopharmacol; 2019 Apr; 33(4):522-531. PubMed ID: 30789308
[TBL] [Abstract][Full Text] [Related]
4. Characterisation of Agomelatine-Induced Increase in Liver Enzymes: Frequency and Risk Factors Determined from a Pooled Analysis of 7605 Treated Patients.
Perlemuter G; Cacoub P; Valla D; Guyader D; Saba B; Batailler C; Moore K
CNS Drugs; 2016 Sep; 30(9):877-88. PubMed ID: 27342740
[TBL] [Abstract][Full Text] [Related]
5. Agomelatine-induced liver injury in a patient with choledocholithiasis.
Eder P; Permoda-Osip A; Majewski P; Linke K; Rybakowski JK
Acta Neuropsychiatr; 2015 Feb; 27(1):56-9. PubMed ID: 25335994
[TBL] [Abstract][Full Text] [Related]
6. CYP1A2 polymorphism in Chinese patients with acute liver injury induced by Polygonum multiflorum.
Ma KF; Zhang XG; Jia HY
Genet Mol Res; 2014 Jul; 13(3):5637-43. PubMed ID: 25117321
[TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of agomelatine: focus on hepatotoxicity.
Gahr M; Kratzer W; Fuchs M; Connemann BJ
Curr Drug Metab; 2014; 15(7):694-702. PubMed ID: 25255870
[TBL] [Abstract][Full Text] [Related]
8. Agomelatine Drug Utilisation Study in Selected European Countries: A Multinational, Observational Study to Assess Effectiveness of Risk-Minimisation Measures.
Jacquot E; Collin E; Ladner A; Tormos A; Hamm L; Perez-Gutthann S; Gutierrez L; Chirila C; Deltour N
Pharmaceut Med; 2019 Aug; 33(4):311-319. PubMed ID: 31933191
[TBL] [Abstract][Full Text] [Related]
9. Agomelatine: an antidepressant with new potent hepatoprotective effects on paracetamol-induced liver damage in rats.
Karakus E; Halici Z; Albayrak A; Polat B; Bayir Y; Kiki I; Cadirci E; Topcu A; Aksak S
Hum Exp Toxicol; 2013 Aug; 32(8):846-57. PubMed ID: 23584358
[TBL] [Abstract][Full Text] [Related]
10. Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study.
Stein DJ; Ahokas A; Albarran C; Olivier V; Allgulander C
J Clin Psychiatry; 2012 Jul; 73(7):1002-8. PubMed ID: 22901350
[TBL] [Abstract][Full Text] [Related]
11. Agomelatine-induced hepatotoxicity.
Štuhec M
Wien Klin Wochenschr; 2013 Apr; 125(7-8):225-6. PubMed ID: 23519541
[No Abstract] [Full Text] [Related]
12. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial.
Goodwin GM; Emsley R; Rembry S; Rouillon F;
J Clin Psychiatry; 2009 Aug; 70(8):1128-37. PubMed ID: 19689920
[TBL] [Abstract][Full Text] [Related]
13. Human cytochrome P4501A2.
Landi MT; Sinha R; Lang NP; Kadlubar FF
IARC Sci Publ; 1999; (148):173-95. PubMed ID: 10493258
[TBL] [Abstract][Full Text] [Related]
14. CYP1A2 rs762551 polymorphism contributes to risk of lung cancer: a meta-analysis.
Ma Z; Guo W; Gong T; Niu HJ; Wang RW; Jiang YG
Tumour Biol; 2014 Mar; 35(3):2253-7. PubMed ID: 24293373
[TBL] [Abstract][Full Text] [Related]
15. CYP1A2 rs762551 polymorphism and risk for amyotrophic lateral sclerosis.
Siokas V; Karampinis E; Aloizou AM; Mentis AA; Liakos P; Papadimitriou D; Liampas I; Nasios G; Bogdanos DP; Hadjigeorgiou GM; Dardiotis E
Neurol Sci; 2021 Jan; 42(1):175-182. PubMed ID: 32592103
[TBL] [Abstract][Full Text] [Related]
16. Association between the CYP1A2 rs762551 Polymorphism and Bladder Cancer Susceptibility: a Meta-Analysis Based on Case-Control Studies.
Zeng Y; Jiang HY; Wei L; Xu WD; Wang YJ; Wang YD; Liu C
Asian Pac J Cancer Prev; 2015; 16(16):7249-54. PubMed ID: 26514519
[TBL] [Abstract][Full Text] [Related]
17. Focus on agomelatine.
Green B
Curr Med Res Opin; 2011 Apr; 27(4):745-9. PubMed ID: 21271795
[TBL] [Abstract][Full Text] [Related]
18. CYP enzyme polymorphisms and susceptibility to HCV-related chronic liver disease and liver cancer.
Silvestri L; Sonzogni L; De Silvestri A; Gritti C; Foti L; Zavaglia C; Leveri M; Cividini A; Mondelli MU; Civardi E; Silini EM
Int J Cancer; 2003 Apr; 104(3):310-7. PubMed ID: 12569554
[TBL] [Abstract][Full Text] [Related]
19. Agomelatine-induced akathisia with concomitant duloxetine medication: a case report.
Imboden C; Hatzinger M
Pharmacopsychiatry; 2012 Jun; 45(4):162-3. PubMed ID: 22290205
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of hepatic cytochrome P-450 isoforms and PPAR-gamma: their role in hepatic injury and proinflammatory responses in a double-hit model of hemorrhage and sepsis.
Higuchi S; Wu R; Zhou M; Ravikumar TS; Wang P
J Surg Res; 2007 Jan; 137(1):46-52. PubMed ID: 17101152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
